Ranbaxy gets supplier quality awardPTIAug 25, 2005, 03.59pm IST

MUMBAI: Ranbaxy Laboratories Ltd on thursday said its US subsidiary Ranbaxy Pharmaceuticals Inc(RPI) has received the Supplier Quality Award from Cardinal Health, the second largest wholesaler in US.The award has been conferred to the company for its services that supported the Cardinal Health pharmaceutical distribution for the period July 2004 to June 2005, Ranbaxy informed the Bombay Stock Exchange.Earlier in June this year, RPI had also received the Supplier Award from Wal-Mart, the largest chain store in the US, for outstanding performance in the first quarter of 2005, it said."We are, delighted to receive our first Supplier Quality Award from Cardinal Health Pharmaceutical Distribution. The recognition reflects the team's hard work, dedication and joint effort," said Bill Winter, Executive Director of Sales, RPI.Ranbaxy Pharmaceuticals Inc (RPI) based in Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories and is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.Ranbaxy partners with Validus to sell calcium drug in USPTISep 3, 2009, 03.05pm IST

NEW DELHI:Ranbaxy Laboratorieson Thursday said it has entered into an agreement with the US-based Validus Pharma for selling low cost versions of its calcium drug Rocaltrol.The company's US-based subsidiary Ranbaxy Pharmaceuticals Inc (RPI) and Validus Pharmaceuticals LLC have entered into an agreement for marketing and distribution of a generic version of Rocaltrol (calcitriol), Gurgaon-based Ranbaxy Lab said in a statement.Under the agreement, Rambaxy would market and distribute an authorized generic version of Rocaltrol in both softgel capsules and an oral liquid formulation.According to industry estimate, overall market sales for calcitriol softgel capsules and oral liquid is about USD 70 million.Ranbaxy will launch the product immediately in the United States and expects to be the only generic company offering all forms and strengths of generic Rocaltrol."Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol," RPI's Sales and Distribution Vice-President Jim Meehan said. We look forward to a long and prosperous partnership with Validus, Meehan added.Rocaltrol is the brand name for a synthetic form of calcitriol, a metabolite of vitamin D, which occurs naturally in the human body.Ranbaxy Laboratories launches generic Cadeut in the American marketPTIDec 6, 2011, 05.31pm IST

Tags: Ranbaxy Laboratories| Pfizer Inc .| CaduetNEW DELHI: Drug firmRanbaxy Laboratorieson Tuesday launched a generic version of Caduet, used for treating cardio vascular diseases, in the US market, as part of an agreement withPfizerInc.The company's wholly-owned subsidiary Ranbaxy Pharmaceuticals Inc has launched genericCaduetindicated for patients suffering from both high-blood pressure and high levels of cholesterol, Ranbaxy said in a statement.he Gurgaon-based firm, however, did not disclose the terms of the agreement with Pfizer.Ranbaxy Senior Vice President and Regional Director Americas Venkat Krishnan said: "Atorvastatin-Amlodipine besylate tablet is a significant and important addition to our portfolio of cardio-vascular products, in the US."Caduet presently marketed by Pfizer is a fixed-dose combination of Atorvastatin-Amlodipine besylate which also contains a crystalline form of Atorvastatin, Ranbaxy said.According to IMS-MAT September 2011, Caduet generated total annual sales of USD 339 million in the US, it added.The company is making available the full range of the generic version of Caduet, the company said.Ranbaxy Laboratories, last week launched a generic version of blockbuster cholesterol-lowering drug Lipitor, which is also a Pfizer brand, in the US market.Ranbaxy, a part of the Daiichi Sankyo Group, has presence in 125 countries with operations in 46 countries.Ranbaxy plans to re-launch skincare brand Sotret in USKhomba Singh, ET BureauMay 21, 2012, 02.45AM IST

Tags: US Food and Drug Administration| united states| Ranbaxy Laboratories| Cipher Pharmaceuticals Ltd.NEW DELHI: India's largest drug makerRanbaxy Laboratoriesplans to re-launch its former flagship skincare brand Sotret in the US, that has been banned for almost four years, through a marketing partnership with a Canadian firm Cipher Pharmaceuticals Ltd."Pre-commercial activities are underway with Ranbaxy Pharmaceuticals, the company's US partner, for a possible launch (of CIP isotretinoin, chemical name of Sotret) in Q4, 2012," Cipher Inc said in its quarterly result report earlier this month.The US drug regulator will have a final review of the drug on May 29, it said. Cipher specialises in developing improved formulations of existing drugs and out-licenses them to partners for a fee. CIP isotretinoin is a new formulation and will be manufactured by Cipher, its CEO Larry Andrews told ET."The plan is to re-launch Sotret, our flagship product in this segment (dermatology), at the earliest," Ranbaxy's CEO and MD Arun Sawhney said in its latest annual report, without specifying details. He said the launch was part of the Gurgaon-based company's strategy to focus on dermatology to strengthen its presence in the branded business.Before a ban in 2008, Sotret was Ranbaxy's third best selling drug globally and was estimated to have generated over $50 million in annual sales. In September 2008,US Food and Drug Administration(FDA) banned 30 drugs, including Sotret, made at the firm's two Indian plants for violating US drug manufacturing norms.According to US-based Zacks Small-Cap Research, a research firm that tracks small companies, Ranbaxy is the exclusive partner to market and distribute the drug in the US. The company partly funded the drug's safety studies and will also pay royalty in mid-teens on net sales of the drug to the Canadian firm. Ranbaxy declined to comment on a query seeking details about the launch and whether the company plans to launch its drug independently.Among the 30 banned drugs, some were yet to be launched at the time of ban. Ranbaxy managed to launch most of the key ones, notably atorvastatin, the world's best selling drug, by transferring the marketing application and production of the drug to its American plant in New Jersey. Sotret is possibly the first drug that was pulled off from the market, which the company is planning to relaunch.FDA had allowed Ranbaxy to sell those batches of Sotret that were already in the market, but the company had to withdraw even those in 2009 after the drug failed a stability test.Ranbaxy LaboratoriesFrom Wikipedia, the free encyclopediaRanbaxy Laboratories Limited

TypePublic

Traded asBSE:500359NSE:RANBAXY

IndustryPharmaceuticals

FateTakeoverbyDaiichi Sankyo

Founded1961

HeadquartersGurgaon,Haryana,India

Revenue9976.9crore(US$1.6billion)(2011)[1]

Net incomeEBITDA1829.9crore(US$290million)(2011)

Employees10,435[1]

ParentDaiichi Sankyo

Websitewww.ranbaxy.com

Ranbaxy Laboratories Limited(BSE:500359) is an Indian multinationalpharmaceuticalcompany that was incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical companyDaiichi Sankyoacquired a controlling share in 2008.[2]Ranbaxy exports its products to 125 countries with ground operations in 43 and manufacturing facilities in eight countries.[3]In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award.Contents[hide] 1History 1.1Formation 1.2Trading 1.3Issues 1.4Acquisition 2See also 3Notes 4External linksHistory[edit source|editbeta]Formation[edit source|editbeta]Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese companyShionogi. The name Ranbaxy is a portmanteau of the names of its first ownersRanbir and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir and Gurbax. After Bhai Mohan Singh's son Parvinder Singh joined the company in 1967, the company saw an increase in scale.Trading[edit source|editbeta]In 1998, Ranbaxy entered theUnited States, the world's largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005.[citation needed]For the twelve months ending on 31st December 2005, the company's global sales were at US$1,178 million with overseas markets accounting for 75% of global sales (USA: 28%,Europe: 17%,Brazil,Russia, andChina: 29%). For the twelve months ending on 31st December 2006, the company's global sales were at US$1,300 million.Most of Ranbaxy's products are manufactured under licence from foreign pharmaceutical developers, though a significant percentage of their products are off-patentdrugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version ofPfizer'scholesterol-cutting drugLipitor, which has annual sales of more than $10 billion.[4]In June 2008, Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium, the generic version of Lipitor and Atorvastatin Calcium-Amylodipine Besylate, the generic version of Pfizer's Caduet in the US starting on the 30th November 2011. The settlement also resolved several other disputes in other countries.[citation needed]On 23rd June 2006, Ranbaxy received from the United StatesFood & Drug Administrationa 180-day exclusivity period to sellsimvastatin(Zocor) in the US as ageneric drugat 80mg strength. Ranbaxy competes with the maker of brand-name Zocor,Merck & Co.; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80mg; andDr. Reddy's Laboratories, also from India, whose authorised generic version (licensed by Merck) is exempt from exclusivity.In June 2008, Japan'sDaiichi Sankyo Companytook a majority (50.1%) stake in Ranbaxy, with a deal valued at about US$4.6 billion. Ranbaxy'sMalvinder Singhremained as CEO after the transaction.[5]On 1st December 2011, Ranbaxy got the much-awaited approval from the US Food and Drug Administration to launch the generic version of drug lipitor in theUnited States of Americaafter its patent expired.[6][7]Issues[edit source|editbeta]During 2004-2005, Dinesh Thakur and Rajinder Kumar, two Indian employees of Ranbaxy, blew the whistle on Ranbaxy's fabrication of drug test reports. Thakur's office computer was soon found tampered with. Ranbaxy then accused Thakur of visiting graphic websites using his office computer, forcing him to resign in 2005. Thakur escaped from India to the USA and contacted theFood and Drug Administrationwhich started investigating his claims.[8]As a result, on 16th September 2008, the Food and Drug Administration issued two Warning Letters to Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India.[9]By 25th February 2009 the US Food and Drug Administration said it halted reviews of all drug applications including data developed at Ranbaxy's Paonta Sahib plant in India because of a practice of falsified data and test results in approved and pending drug applications.[10]On 8th February 2012, three batches of the gastric acid secretion inhibitor Pantoprazole (PPI-Inhibitor) were recalled in The Netherlands due to the presence of impurities.[11]On 9th November 2012, Ranbaxy halted production and recalled forty-one lots ofatorvastatindue to glass particles being found in some bottles.[12][13]In May 2013 the US fined the company US$500 million after found guilty of misrepresenting clinical generic drug data and selling adulterated drugs to the United States.[14]Ranbaxy is among the leading manufacturer of generic medicines in India along with it peers Sun Pharmaceutical , Lupin and Aurbindo Pharma.Acquisition[edit source|editbeta]In June 2008,Daiichi-Sankyoacquired a 34.8% stake inRanbaxy,[15][16]for a value $2.4 billion. In November 2008,Daiichi-Sankyocompleted the takeover of the company from the founding Singh family in a deal worth $4.6 billion[17]by acquiring a 63.92% stake in Ranbaxy.The addition of Ranbaxy Laboratories extends Daiichi-Sankyo's operations - already comprising businesses in 22 countries.[citation needed]The combined company is worth about US$30 billion.[18]In 2009 it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the India operations of Ranbaxy Laboratories.[19][20]Ranbaxy gains 34%: Five reasons why the stock was on a highECONOMICTIMES.COMAug 8, 2013, 05.00PM IST

Tags: united states| Sun Pharma| stocks| Shares| Ranbaxy Laboratories| Market| Malaysia| FDA| earnings| BSE| Bombay stock exchange| Africa (The surge comes on a day when)NEW DELHI: Shares ofRanbaxyrallied 34 per cent in intraday trade on the BSE on Thursday, a day when Malaysia allocatedRMSB, its joint venture with Malaysian shareholders, space for setting up agreenfieldmanufacturing unit; and also a day after the company reported earnings for the second quarter of the calendar year 2013.

The pharma major finally ended 27.49 per cent higher at Rs 359.40, from Wednesday's closing price of Rs 281.90. It hit a low of Rs 279 and a high of Rs 377.70 in the intraday trade on the Bombay Stock Exchange (BSE).Ranbaxy Labs posted a consolidated net loss of Rs 524.24 crore for the quarter ended June 30, 2013, mainly on account of foreign exchange losses and goodwill impairment in its operations in France.However, analysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a limited risk given the fact the stock has already corrected a lot so far in 2013.We have collated top five reasons which could have aided the sharp rise in the stock price of Ranbaxy in today's trade:NOD FOR MANUFACTURING FACILITY IN MALAYSIARanbaxy Laboratories said that Ranbaxy Malaysia Sdn Bhd (RMSB), its joint venture with Malaysian shareholders, has been allocated site for setting up a greenfield manufacturing facility in Malaysia.The JV company signed a 'letter of offer' agreement with Kulim Hi Tech Park (KHTP), a wholly owned state agency and industrial park that houses various other leading industries located at Kulim, Ranbaxy Laboratories said.Ranbaxy Laboratories holds a 71 per cent stake in the joint venture RMSB.MARGIN IMPROVEMENTWith strong operating performance and sales especially in US showing some sort of uptick in the base business is a positive sign for the pharma major, say analysts.Core OPM picked up sharply at 9.8 per cent as compared to 7.6 per cent reported in 1Q. The management expects to scale up margins in coming quarters led by led by market share gains on Isotretinoin (from c. 14%), Africa+India biz recovery and strengthening manufacturing processes."Management guides gradual recovery in base margins, QoQ pick up in contractual payment from one time DOJ settlement related expense (non-recurring), step down of consent decree expense from 1QC14," Sbicap Securities said in a report.ROBUST US SALES IN THE QUARTER"With healthy market share in generic Actos and Evoxac, along with scale up in Absorica, Ranbaxy's base business is strengthening," Elara Securities said in a report.The company remains confident of monetizing generic Diovan and Valcyte (expecting launch in September 2013) this year. The company paid out US$ 500mn to the US FDA and DoJ during the quarter," added the report.US quarter run rate have further improved to $138mn from $110mn QoQ, led by MS gains in Absorica (14% vs. 10% qoq)."Further traction in Absorica along with potential launches in Diovan (4QC13), Valcyte (4QC13) and Nexium (2QC14) expects to result in $626/$922mn in Sales for C13/14e," say analysts.STOCK WAS HIGHLY OVERSOLD AHEAD OF RESULTSShares of Ranbaxy Laboratories came under pressure earlier in the year after the drug maker pleaded guilty to US felony charges related to drug safety and agreed to pay $500 million in settlement.Ranbaxy Laboratories has plunged over 40 per cent so far in the year 2013 (as of data collected on August 7) largely on account of USFDA concerns."My sense is Ranbaxy is the next Sun Pharma or the next big story in the pharma space that is emerging, and if somebody has a patience I would look at it with a potential to be into the Rs 1000 category in probably about 18 months' time," said Prakash Diwan, Director, Altamount Capital Management in an interview with ET Now."We need to have some patience but it is finally good time as next set of earnings will not only show some growth in top line but it will also shows some new products getting accepted in a significant way for the company," he added.BROKERAGE VIEWSAnalysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a limited risk given the fact the stock has already corrected a lot so far in 2013.As much as six global brokerage houses have 'buy' or an 'overweight' rating on Ranbaxy Laboratories post the Q2 results, but most of them have also revised their target price downwards.With strong operating performance and sales especially in US showing some sort of uptick in the base business is a positive sign for the pharma major, say analysts.

Ads by GoogleRanbaxy spurts 34% as Malaysia allots site for manufacturing unitECONOMICTIMES.COMAug 8, 2013, 03.30PM IST

Tags: united states| Shares| Ranbaxy Laboratories| Pharma| markets| France| earnings (Most brokerage firms are)NEW DELHI:Sharesofdrug majorRanbaxy Laboratoriessaw a sudden spurt in intraday trade, rising as much as 15% on the NSE, and a little below that level on the BSE, as its joint venture with Malaysian shareholders - Ranbaxy Malaysia Sdn Bhd (RMSB) - was allocated site for setting up a greenfield manufacturing facility in Malaysia.

The stock rallied as much as 34 per cent in afternoon trade on the BSE to touch its intraday high of Rs 377.70.On Wednesday, Ranbaxy Labs posted a consolidated net loss of Rs 524.24 crore for the quarter ended June 30, mainly on account of foreign exchange losses and goodwill impairment in its operations inFrance. However, analysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a limited risk given the fact the stock has already corrected a lot so far in 2013.Shares of Ranbaxy Laboratories came under pressure earlier in the year after the drug maker pleaded guilty to U.S. felony charges related to drug safety and agreed to pay $500 million in settlement.Ranbaxy Laboratories has plunged over 40 per cent so far in the year 2013 (as of data collected on August 7) largely on account of USFDA concerns.As much as six global brokerage houses have 'buy' or an 'overweight' rating on Ranbaxy Laboratories post the Q2 results, but most of them have also revised their target price downwards.The company's CEO said in an analyst on Wednesday said that during the quarter, 16 national regulatory agencies have inspected various facilities of the company.With strong operating performance and sales especially in US showing some sort of uptick in the base business is a positive sign for thepharmamajor, say analysts.The net sales came in at Rs 2,663.3 crore a decline of 17.8 per cent in sales. This was much lower than expectation of Rs 2,850cr during 2QCY2013.However, excluding the exclusivities - the base business clocked a double digit growth during the period."The growth was mainly lead by the branded business Emerging business of LATAM and branded business of Africa, APAC and Russia Indian sales during the period came in flat, on back of the new drug policy," Sarabjit Kour Nangra, VP-Research, Pharma at Angel Broking."On back of attractive valuations, we maintain our buy on the stock," added Nangra.Ranbaxy CEO & managing director Arun Sawhney said in an analyst call on Wednesday evening that absolute sales were lower because in the corresponding quarter last year the sales included contribution from 180 days marketing exclusivity opportunities in the US market.Ads by Google Dental Implants SurgeryDental Implants at Affordable Price Lifetime Warranty. MDS Dentist.www.signaturesmiles.in Aviva i-Life Term PlanPay Only Rs.16*/day and Get 1 Crore Life Cover+ Tax Benefits. Buy Now!www.avivaindia.com/Term-Plan"Growth levers remains intact for Ranbaxy as operating leverage through product approvals or facility utilisation, near-term FTF monetization (Diovan, Valcyte) and market share pick up in the branded derma portfolio will all lead to margin expansion," Sbicap Securities said in a note."We expect base biz valuation to unlock over with clarity emerging towards resumption US supplies from Dewas," added the report.Sbicap is of the view that the US quarter run rates have further improved to $138mn from $110 mn reported in the previous quarter, led by MS gains in Absorica (14% vs. 10% qoq).We have collated recommendations from various brokerage firms on 12-months target price of Ranbaxy post Q2 results:-Ads by GoogleDespite regulatory issues, Ranbaxy Laboratories remains a high-risk, high-return stockNarendra Nathan, ET BureauAug 12, 2013, 08.00AM IST

Tags: US FDA| stocks| Ranbaxy Laboratories| Ranbaxy| Paonta Sahib| North America| ET Wealth| Drugs Price Control Order| Abbreviated New Drug Application (Despite good results, the)The analyst community is taking a bullish stand onRanbaxyLaboratories despite a fall in net sales and EBITDA in the second quarter of 2013, because the quarterly numbers were better than the street expectations. During this period, the 9.8 per cent adjusted EBITDA margin was much higher compared with the expected value of 8 per cent, and the first quarter value of 6.4 per cent.

The improving visibility about the company's prospects is another reason for this sudden turnaround in sentiments. The company's sales fromNorth Americarose 23.6 per cent on a quarter-over-quarter basis despite its ongoing problems with the US Food and Drug Administration (FDA). Ranbaxy's operating margins are at very low levels compared to its peers, primarily because of the continuing expenses to improve its Dewas andPaonta Sahibfacilities to comply with the US FDA's consent decree.

However, these expenses are expected to taper off after 2014. This means that the margin improvement is inevitable in the next two years, when all theUS FDAissues are resolved. Once this happens, the US sales will receive a major boost and Ranbaxy will start getting ANDA (Abbreviated New Drug Application) approvals from the FDA. The DPCO (Drugs Price Control Order) is another issue that the company has to grapple with and its domestic sales remained flat in the second quarter due to this.Though the compulsory reduction of essential drug prices will affect the entire pharma industry, the Ranbaxy management has indicated an 8 per cent impact on its domestic business due to this. The issue may get resolved after the 2014 general elections.SinceRanbaxy Laboratoriesis still grappling with the US FDA and DPCO issue, it is a high-risk, high-return bet and, therefore, investors with a moderate risk appetite can consider this counter for parking their long-term money.Its valuation has also reached the desired level due to continuousunderperformanceas is evident from the relative performance chart. However, the massive short-covering after the better-than-expected second quarter numbers reduced this gap from 59 per cent to 37 per cent one week earlier. So, investors need to wait for a correction in this stock to enter it.

Selection methodology:We pick the stock that has shown the maximum increase in consensus analyst rating during the past month. Consensus rating is arrived at by averaging all analyst recommendations after attributing weightages to each of them (5 for strong buy, 4 for buy, 3 for hold, 2 for sell and 1 for strong sell) and any improvement in the rating indicates that the analysts are becoming more bullish on the stock.To ensure that we pick only those companies that have a decent analyst coverage, this search is restricted tostocksthat have been covered by at least 10 analysts.

Ads by GoogleWhy Ranbaxy is up over 35% after posting Q2 lossNDTV | Updated On: August 08, 2013 15:27 (IST)

Ranbaxy shares jumped over 35 per cent toRs.380 on Thursday, a day after India's top drugmaker (by sales) reported a net loss ofRs.524 crore for the June quarter. Ranbaxy was the top gainer on the 50-share Nifty benchmark.Here's why the stock is up today:

1. Strong growth in U.S.: Ranbaxy's dollar revenues were encouraging, with the U.S. business reporting a 25 per cent sequential growth. U.S. is the biggest drug market for Ranbaxy. Global investment bank Macquarie said U.S. sales were driven by the newly launched acne treatment drug Absorica, which could see much higher sales in future. Macquarie has an "outperform" rating on Ranbaxy.2. Operationally strong: Ranbaxy posted a loss ofRs.524 crore in the June quarter, but these losses were not related to Ranbaxy's core business. Ranbaxy operates in a number of countries and generates revenue in different currencies. The company said it incurred forex loss ofRs.540 crore in the June quarter. It wrote off anotherRs.120 crore in loss of goodwill at its overseas subsidiaries. Negative publicity about a firm can create goodwill impairment, as can the reduction of brand-name recognition. Ranbaxy has been in news for all the wrong reasons - its factories have been banned by the US regulator, it has been pulled up by the European Union and the company has been dragged into litigation in India -- recently.3. Sales in line: Ranbaxy posed a 17 per cent year-on-year drop in sales atRs.2,633 crore. However, revenues were in line with Street estimates. Stocks tend to react positively if operational numbers like sales and profit beat or meet analyst estimates.4. Margins surprise: Ranbaxy's gross margins rose sequentially, beating estimates. EBITDA (Earnings before interest, tax, depreciation and amortization) margins, a key indicator of profitability, rose 450 basis points sequentially. Ranbaxy's management guided for margin recovery over next 18-24 months.5. Ranbaxy attractive bet after recent fall: Ranbaxy shares have fallen sharply since the drugmaker decided to pay $500 million in civil and criminal fines under a settlement agreement with the US Department of Justice. The stock has fallen 30 per cent over the last three months, while the broader BSE healthcare benchmark, comprising other drugmakers, has remained flat. Analysts say Ranbaxy shares have become attractive after the sharp fall.Evidence against Ranbaxy likely to be furnished in SCCNN-IBN|Posted on Aug 12, 2013 at 09:00am ISTShareIs Jesus Really God?

Discover the Evidence From Scholars About Jesus' Claims to be GodY-Jesus.com

Ads by Google

New Delhi:Evidence in a case againstRanbaxyis likely to be furnished in the Supreme Court on Monday. Earlier in August, the Supreme Court while replying to a petition seeking cancellation of Ranbaxy's manufacturing licence had said that the petitioner can file the documents to prove that the company sold adulterated drugs.The Supreme Court had on June 25 dismissed a PIL which had alleged that Ranbaxy manufactured and sold adulterateddrugs. The court in its order said that there is no evidence to show that the pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to bring in evidence against Ranbaxy.The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard andadulterated drugs. The pharma giant was asked to pay a fine of 500 million dollars

The Supreme Court had on June 25 dismissed a PIL which had alleged that Ranbaxy manufactured and sold adulterated drugs.

We offer High Quality, Affordable PharmaceuticalsWe, at Ranbaxy, are committed to providing affordable pharmaceutical products of global quality standards to patients all over the world. In our manufacturing facilities, approved by various regulatory bodies in the U.S., Europe, Africa, Asia Pacific and Latin America, we manufacture Generics, Differentiated products, Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.We manufacture and market over 500 molecules and their combinations in multiple dosage forms, catering to patient needs in various therapies. These include Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. In several countries, Ranbaxy ranks among the leading companies in these therapy areas.Our presence in more than 150 countries helps us in being responsive to local treatment needs while continually improving our global product portfolio.Our unique hybrid business model, involving synergistic collaboration with Daiichi Sankyo, gives us access to originator products in various markets around the world. We are among the very few global pharmaceutical companies that offer a wide range of both generic and innovator products.Top Products of RanbaxyMoleculeDrug Class

Atorvastatin & CombinationsHypolipidemics

DonepezilAnti-Alzheimers

ValacyclovirAnti-Virals

SimvastatinHypolipidemics

Amoxicillin+Clavulanic AcidAnti-bacterials

KetorolacAnalgesics

Ciprofloxacin & CombinationsAnti-bacterials

Imipenem + CilastatinAnti-bacterials

Loratadine & CombinationsAnti-histaminics

Fenofibrate & CombinationsHypolipidemics

Amoxicillin & CombinationsAnti-bacterials

CephalexinAnti-bacterials

ClarithromycinAnti-bacterials

AmbazoneOral Antiseptics

Pantoprazole & CombinationsProton Pump Inhibitor

Therapy Areas Anti-infectivesWe have a significant presence in the Anti-infectives segment havingRead More CardiovascularCardiovascular (CVS) ailments are on the rise all over the world due to changingRead More Pain and MusculoskeletalSome of our best-selling molecules in the Pain and MusculoskeletalRead More GastrointestinalGastrointestinal is another significant therapeutic segment for usRead More RespiratoryThere is a growing global population of patients with ailments relating toRead More Central Nervous SystemWe have a wide portfolio of drugs for Central Nervous System (CNS)Read More Anti-retroviralsWe offer a wide range of World Health Organisation (WHO)Read More DermatologyWe have a major focus in Dermatology with a presence across marketsRead More

Branded Pharmaceuticals BusinessOur branded pharmaceuticals business, Ranbaxy Laboratories Inc. (RLI), is committed to developing a distinguished branded pharmaceutical business. The foundation for establishing the branded business rests on three strategic pillars:1. Licensing/acquisitions2. In-house product development3. Marketing alliancesWe are actively looking to acquire more products in order to augment RLIs product offerings to customers.An important factor in the growth of our branded business is product development expertise. We have highly advanced capabilities in Novel Drug Delivery Systems (NDDS) that offer new and improved formulations to currently available chemical entities. For example, we have developed a once-daily formulation of the anti-infective Cipro (ciprofloxacin), which we have licensed to Bayer, the original marketer of the drug.We hope to take advantage of our product development expertise by launching our own proprietary brands, which are currently at various stages of development.With a well-defined branded product portfolio, we are actively looking for marketing partners with complementary skills and needs.Our branded prescription division in the US market will expand and grow through our global R&D efforts, continued exploration of NDDS; licensing activities; and mergers and acquisitions. Our commitment to invest significantly in R&D will translate into the development of innovative branded products with a wide range of therapeutic uses.Products List of RANBAXY (C V)

ANGISTAT 2.5MG CAPSANGISTAT 6.5MG CAPS

CANDESAR 4MG TABCANDESAR 8MG TAB

CARDIBETA 100MG TAProducts List of RANBAXY (CHC)

CHERICOF SOFTGELSCHERICOF SYRUP(LARGE)

CHERICOF SYRUP(SMALL)GARLIC PEARLS(100`S)

GARLIC PEARLS(30`S)OLESAN OIL

PEPFIZ TAB 2`S (EACH)PEPFLUX GEL(GINGER)

PEPFLUX GEL(LEMON)REVITAL CAPS(10`S PACK)

REVITAL CAPS(30`S PACK)REVITAL CAPS(60`S PACK)

REVITAL LIQREVITAL SENIOR TAB (10`S PACK)

REVITAL SENIOR TAB (30`S PACK)REVITAL WOMAN TAB (10`S PACK)

REVITAL WOMAN TAB (30`S PACK)REVITALITE POWDER

VOLINI ACTIVE GELVOLINI DUO TAB

VOLINI GEL SACHET(TUBE)VOLINI GEL(LARGE-50GM)

VOLINI GEL(MEDIUM-30GM)VOLINI GEL(SMALL-15GM)

VOLINI SPRAY (LARGE)VOLINI SPRAY (SMALL)

VOLINI TABS

CARDIBETA 12.5MG TAB

CARDIBETA XR 12.5MG TABCARDIBETA XR 25MG TAB

CARDIBETA XR 50MG TABCARDIBETA-AM TAB

CARDIBETA-AMF TABCOVAMLO TAB

COVANCE-25MG TAB(10`S STRIP)COVANCE-50MG TAB(10`S STRIP)

COVANCE-50MG(CP-30`S PK)COVANCE-AT TAB

COVANCE-D (CP 30`S PACK)COVANCE-D TAB(10`S STRIP)

FLOTHIN 40MG/0.4ML(EACH)

RevitalBrand:Ranbaxy|Manufacturer:|COD Available|Dispatched in:1 - 3 working days11 Reviews Description Recommended Products Hectic lifestyles tend to cause fatigue in today's fast paced time,Revitalcan keep you healthy to face all this. Ithelps in providing the body with the right amountof vitamins, minerals and ginseng. Now you can get through the day with just one capsule a day.Revitalnot only rejuvenates your low energy level but it also keeps you fresh and active throughout the day. Loaded with essential vitamins and the minerals, one capsule is sufficient to meet your daily dose of health and keep you physically active and mentally alert.2variants available.Please select Desired Product Variant(s) Flavor:NASIZE:30 CapsRs 270Bottom of FormTop of Form

Flavor:NASIZE:60 CapsRs 522Rs 4965%off

Bottom of Form

DescriptionRevitalis a daily food supplement that has a balanced combination of vitamins, minerals and ginseng. Ginseng is an herb commonly used to increase energy and well being. The amount of vitamins and minerals cover the daily requirements of an individual. It helps in decreasing fatigue, it improves endurance, tolerance and compatibility during stress, it improves concentration, learning and memory and it can be taken by both males and females over 12 years of age. Suitable for diabetics as it does not contain sugar.DetailEach capsules contain ginseng extract power which is highly concentrated,standardized ginseng extract, calcium, phosphorous, vitamin c, ferrous, zinc, nicotinamide, calcium, vitamin e, magnesium, potassium, vitamin, b2, vitamin b1, vitamin b6, manganese, copper and folic acid.Features And Benefits It is beneficial for both men and women. It increases energy levels of the body. It provides the body with essential supplements. It contains important minerals and vitamins.Supplement FactsServingSize 1 CapsuleAmount per Serving% Daily Value

Energy4.23 kcal

Carbohydrate0.10g

Protein0.02g

Fat0.38g

Vitamin A2000 IU

Vitamin B11mg

Vitamin B21.5mg

Vitamin B310mg

Vitamin B55mg

Vitamin B61mg

Vitamin B121mcg

Vitamin C40mg

Vitamin D3200IU

Vitamin E5mg

Folic Acid0.12mg

Calcium75mg

Phosphorus58mg

Ferrous Fumarate17mg

Zinc10mg

Magnesium3mg

Pottasium2mg

Manganese0.5mg

Copper0.5mg

Iodine0.1mg

Ginseng extract powder42.5mg

Other IngredientsNone.

How to useTake 1 capsule per day preferable after a meal.

Allergen Information/Warning:Revital may have some side effects on certain people. It must not be taken on an empty stomach and if done so rare side effects such as indigestion, heartburn or nausea might occur. Consult your physician prior to taking Revital if you are pregnant and lactating.

Ranbaxy Garlic PearlsBrand:Ranbaxy|COD Available|Dispatched in:1 - 3 working days1 Reviews Description The Ranbaxy Garlic 100 Pearls is a natural supplement for a keeping your heart and digestive system healthy. This product is pretty useful in dealing high blood pressure and protecting body against several diseases of the heart like arteriosclerosis. These garlic pearls from Ranbaxy are extremely popular worldwide and help a great deal in relieving problemssuch as indigestion and gasbuild up in stomach and intestines. This supplement also aids in managing cholesterol levels in your body, dealing with chronic cough and cold problems as well as relieving severe pains in joints.Size:100 pearls per packRs90Flavor:NASIZE:100 PearlsTop of Form

Bottom of Form

Description It is an ideal supplement for matters related to the heart. Garlic is a vegetable with excellent medicinal value which has been tapped the most in this product from Ranbaxy. Indispensable for people with regular digestive disorders It is very active and starts functioning as soon as it reaches the digestive system. Provides immediate relief for person suffering from diseases related to heart, blood pressure, indigestion, chronic cold and coughIngredientsGarlic OilIntake:You are ideally advised to consume two-three pearls twice a day in between two consecutive meals.Caution:It shall be consumed only under medical prescription if there is a case of pregnancy or illness. You must store them in a cool and dry place away from children and pets.go to top

Description It is an ideal supplement for matters related to the heart. Garlic is a vegetable with excellent medicinal value which has been tapped the most in this product from Ranbaxy. Indispensable for people with regular digestive disorders It is very active and starts functioning as soon as it reaches the digestive system. Provides immediate relief for person suffering from diseases related to heart, blood pressure, indigestion, chronic cold and coughIngredientsGarlic OilIntake:You are ideally advised to consume two-three pearls twice a day in between two consecutive meals.Caution:It shall be consumed only under medical prescription if there is a case of pregnancy or illness. You must store them in a cool and dry place away from children and pets.go to top

Revital Senior

Revital SeniorBrand:Ranbaxy|COD Available|Dispatched in:1 - 3 working days3 Reviews Description Special Offers Recommended Products Revital Seniorsis a specially formulated supplement that is enriched with essential Vitamins, Calcium, Ginseng and Minerals ideal for promoting an improved health and stamina in old age. It is a daily health supplement which tackles weariness and fatigue to keep one fresh and active, throughout the day.1variants available.Please select Desired Product Variant(s) DescriptionPriceOrderTop of Form

SIZE:30 CapsRs 295Rs 2882%of

Bottom of FormDescriptionRevital for Seniorsis a combination of ginseng, vitamins and minerals. Ginseng is a herb which increases energy levels of the body. It also contains 13 Vitamins and 17 Minerals meant to keep you healthy and fit even after the age of 50.Features and Benefits Contains Ginseng Improves health and immunity Has an antioxidant property Improves staminaDosageTake 1 tablet daily after any meal.

Ranbaxy Revitalite Protein Powder

Ranbaxy Revitalite Protein PowderBrand:Ranbaxy|COD Available|Dispatched in:1 - 3 working days1 Reviews Description Recommended Products Ranbaxy Revitalite Protein Powder is a total vegetarian protein supplement that contains no flavour, sugar or preservatives.Rs 490Rs475you save3%Flavor:NASIZE:0.44 lb / 0.2 Kg JarTop of FormSold OutDescriptionRanbaxy Revitalite Protein Powder is neutral when it comes to taste and is stable when cooked. You can easily add it to any beverage or food of your choice. Ranbaxy Revitalite Protein Powder is based on soy protein isolate that has 90 percent protein. It offers various benefits for people of all ages.DetailsRanbaxy Revitalite Protein Powder is a great protein supplement that can be added to your regular diet.Features And Benefits It offers immunity and preserves good health. It helps repair daily wear and tear of your body. It helps in taking care of the overall growth and development of your body.Servings Per ContainerSupplement Fact

Serving Size 1 ScoopAmount per Serving% Daily Value

Approximate Composition10g**

Energy36Kcal**

Protein8g**

Carbohydrates0.5**

Fat Content0.3g**

Calcium70mg**

Iron1mg**

Isoleucine408mg**

Leucine696mg**

Methionine224mg**

Phenylalanine752mg**

Threonine320mg**

Tryptophan104mg**

Valine432mg**

Histidine216mg**

How to use:You must mix 1 scoop of Ranbaxy Revitalite Protein Powder to a glass full of water or milk or your favorite beverage.

Storage Instructions :Always ensure to air-tight the container properly after opening it. It is advisable to store the container in a cool and dry place

Bottom of Form